ArticleThe European journal of neuroscience2025
Differences in Performance in the Trail Making Test Part B Between Adoptees With High and Low Genetic Risk for Schizophrenia Spectrum Disorders: The Finnish Adoptive Family Study of Schizophrenia.
Article in The European journal of neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differences in Performance in the Trail Making Test Part B Between Adoptees With High and Low Genetic Risk for Schizophrenia Spectrum Disorders: The Finnish Adoptive Family Study of Schizophrenia.The European journal of neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The current study uses data from the Finnish Adoptive Family Study of Schizophrenia to investigate the association of genetic risk status and diagnosed psychiatric disorders with executive functioning, measured by Trail Making Test Part B (TMT-B), in adoptees with high and low genetic risk for schizophrenia spectrum disorders. The results showed no statistically significant differences in TMT-B completion times between adoptees with high and low genetic risk for schizophrenia spectrum disorders, although adoptees with high genetic risk for schizophrenia spectrum disorders as a group exhibited slightly slower performance. This contradicts previous studies reporting poorer TMT-B performance in unaffected first-degree relatives of individuals with schizophrenia. However, it aligns with studies that did not find differences in TMT-B performance between first-degree relatives of individuals with schizophrenia and controls. Significant differences in TMT-B completion times were observed among adoptees with psychiatric disorders, indicating that psychiatric morbidity associates with TMT-B performance, regardless of genetic risk. These findings indicate that various forms of psychopathology may hinder TMT-B performance, potentially due to reduced processing speeds or increased propensity towards a higher error rate. This highlights the link between psychopathology and cognitive impairment, underscoring this relationship as a critical focus for neuroscience research. Although TMT-B performance did not differ between adoptees with high and low genetic risk for schizophrenia spectrum disorders, our results do not rule out the existence of other cognitive deficits in adoptees with high genetic risk for schizophrenia spectrum disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.